Tower Research Capital LLC (Trc) Vaxcyte, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 14,436 shares of PCVX stock, worth $1.15 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
14,436
Previous 978
1376.07%
Holding current value
$1.15 Million
Previous $111,000
963.96%
% of portfolio
0.02%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding PCVX
# of Institutions
349Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$954 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$843 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$793 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$693 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$495 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.73B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...